Laurence Sanhès
A5003273516- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Cutaneous lymphoproliferative disorders research
- Neutropenia and Cancer Infections
- Hematological disorders and diagnostics
- Immunodeficiency and Autoimmune Disorders
- Histone Deacetylase Inhibitors Research
- Hemoglobinopathies and Related Disorders
- Glioma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Occupational and environmental lung diseases
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- PI3K/AKT/mTOR signaling in cancer
- CAR-T cell therapy research
- Pneumocystis jirovecii pneumonia detection and treatment
Centre Hospitalier de Perpignan
2016-2025
Groupe Francophone des Myélodysplasies
2004-2019
Recherche clinique appliquée à l'hématologie
2018
Assistance Publique – Hôpitaux de Paris
2003-2018
Hôpital Saint-Louis
2016-2018
Université Paris Cité
2016-2018
Délégation Paris 7
2016
Inserm
2003-2012
Institut pour l'avancée des biosciences
2012
Centre Hospitalier Universitaire de Tours
2012
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most have a relapse. We investigated whether fludarabine-containing induction regimen improved the complete-remission rate maintenance therapy rituximab prolonged remission.We randomly assigned 60 years age or lymphoma, stage II to IV, who were not eligible high-dose six cycles rituximab, fludarabine, cyclophosphamide (R-FC) every 28 days eight...
To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy autologous stem-cell transplantation (ASCT) as a first-line treatment primary CNS lymphoma (PCNSL).Immunocompetent patients (18 to 60 years age) with untreated PCNSL were randomly assigned receive WBRT ASCT consolidation after induction consisting two cycles R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 D2, BCNU D3,...
To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas.Patients with histologically confirmed peripheral lymphoma (PTCL) cutaneous who progressed after one more lines prior chemotherapy received at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary points were duration (DOR), progression-free survival (PFS), (OS).Of 60 patients included, 27 (45%) to...
Background. Good syndrome (GS) is a rare condition in which thymoma associated with hypogammaglobulinemia. It characterized by increased susceptibility to bacterial, viral, and fungal infections, as well autoimmunity. Most patients have no circulating B cells.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported of a randomized phase II study patients with newly diagnosed CNS lymphoma (age 18-60 years)....
SummaryBackgroundIn our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared who receive red blood cell transfusion (RBCT). In this study, a follow up time and more included, aimed to assess long-term effects health-related quality of life (HRQoL) exposure or without RBCT syndromes.MethodsThe EUMDS Registry is non-interventional,...
Summary Baseline characteristics, disease‐management and outcome of 1000 lower‐risk myelodysplastic syndrome ( MDS ) patients within the European LeukaemiaNet EUMDS Registry are described in conjunction with validation revised International Prognostic Scoring System IPSS ‐R). The registry confirmed established prognostic factors, such as age, gender World Health Organization 2001 classification. Low quality life EQ ‐5D visual analogue scale score) was significantly associated reduced...
ABSTRACT Rapidly fatal cases of invasive fungal infections due to a fungus later identified as Saprochaete clavata were reported in France May 2012. The objectives this study determine the clonal relatedness isolates and investigate possible sources contamination. A nationwide alert was launched collect cases. Molecular identification methods, whole-genome sequencing (WGS), clone-specific genotyping used analyze recent historical isolates, case-case performed. Isolates from thirty (26...
The GRASPALL/GRAALL-SA2-2008 Phase II trial evaluated the safety and efficacy of L-asparaginase encapsulated within erythrocytes (GRASPA®) in patients ≥ 55 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.Thirty received escalating doses GRASPA® on Day 3 6 induction Phases 1 2. primary endpoint was asparagine depletion < 2 µmol/L for at least 7 days. This reached 85 71% 100 150 IU/kg respectively but not 50 IU/kg. Grade 3/4 infection, hypertransaminasemia,...
BackgroundThe present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens disease progression in multiple myeloma (MM) patients.Patients MethodsAdult patients initiating any new MM therapy from October 2010 2012 were eligible. A multistage patient/site recruitment model was applied minimize the selection bias; enrollment stratified by country, region, practice type. The patient medical features, history, remission status recorded...
Abstract Despite very similar gene expression profiles, the clinical course of B-cell chronic lymphocytic leukemia (B-CLL) is heterogeneous. Immunoglobulin VH (IgVH) mutational status and receptor (BCR) signaling mediators have been associated with disease progression. However, consequences BCR engagement on cell survival evolution remain unclear. We show here that B-CLL dependent threshold stimulation induced by immobilized antibody, in contrast to soluble anti-μ F(ab)′2 which leads...
The efficacy of azacitidine in patients with anemia and lower-risk myelodysplastic syndromes, if relapsing after or resistant to erythropoietic stimulating agents, the benefit combining these agents this setting are not well known. We prospectively compared outcomes patients, all them having characteristics subset syndrome, randomly treated alone combined epoetin-β. High-resolution cytogenetics gene mutation analysis were performed at entry. primary study endpoint was achievement red blood...
Central nervous system (CNS) thrombotic events are a well-known complication of acute lymphoblastic leukemia (ALL) induction therapy, especially with treatments including l-asparaginase (l-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report the 22 CNS venous thrombosis cases occurring 708 adults treated for ALL or lymphoma (LL) Group Research Adult Acute Lymphoblastic Leukemia (GRAALL)-induction protocol, which included eight L-ASP (6,000 IU/m(2) )...
Quantification of minimal residual disease may guide therapeutic strategies in mantle cell lymphoma. While multiparameter flow cytometry is used for diagnosis, the gold standard method analysis real-time quantitative polymerase chain reaction (RQ-PCR). In this European Mantle Cell Lymphoma network (EU-MCL) pilot study, we compared with RQ-PCR detection. Of 113 patients at least one sample, was applicable 97 (86%). A total 284 samples from 61 were analyzed parallel by and RQ-PCR. single,...
High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safety of guadecitabine high-risk syndrome low blast count acute refractory or relapsing azacitidine. We included 56 with median age 75 years [Interquartile Range (IQR) 69-76]. Fifty-five received at...
Rituximab improves progression-free survival (PFS) and time to next treatment (TTNT) when compared with the watch wait strategy for patients low-tumor burden follicular lymphoma (FL). Prolonged rituximab maintenance did not prolong TTNT, whereas it raises concerns about resources use patient adhesion. Our aim was then investigate of short using subcutaneous (SC) route in FL.Patients histologically confirmed CD20+ FL were randomly assigned receive either rituximab, 375 mg/m2 once daily on D1,...